Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis.

By Georgios Chamilos, Russell E. Lewis, D. Kontoyiannis. Clinical Infectious Diseases, 2008

769 citations recorded by the source corpus.

Subfields: Epidemiology, Infectious Diseases, Small Animals

View Paper: https://www.semanticscholar.org/paper/2e8ddb4f9e9741418105a980c686bccd7bf76568

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. J. Guinea
2. M. Pfaller
3. D. Diekema
4. M. Arendrup

In Infectious Diseases

1. J. Guinea
2. M. Pfaller
3. D. Diekema
4. M. Arendrup

In Small Animals

1. J. Guinea
2. M. Pfaller
3. D. Diekema

Citations in the corpus

• Epidemiology of Invasive Mycoses in North America (2010, background): “Amphotericin B seems to be the treatment of choice for P. variotii infections, whereas voriconazole resistance has been described previously (Chamilos et al. 2005).”
• ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. (2014, background): “This is particularly true for a disease that is likely to be underdiagnosed and in which individual prognosis is driven by early treatment [2,27].”